DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Information source: NCIC Clinical Trials Group
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: pegfilgrastim (Biological); docetaxel (Drug); epirubicin hydrochloride (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: NCIC Clinical Trials Group

Official(s) and/or principal investigator(s):
Maureen E. Trudeau, BSc, MA, MD, FRCPC, Study Chair, Affiliation: Edmond Odette Cancer Centre at Sunnybrook

Summary

RATIONALE: Drugs used in chemotherapy such as epirubicin and docetaxel use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as pegfilgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of combining epirubicin and docetaxel with pegfilgrastim in treating women who have locally advanced or inflammatory breast cancer.

Clinical Details

Official title: A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast Cancer

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Toxic effects

Response (phase II)

Detailed description: OBJECTIVES:

- Determine the maximum tolerated dose and recommended phase II dose of docetaxel and

epirubicin when given with pegfilgrastim in women with locally advanced or inflammatory breast cancer. (Phase I, group 1 closed to accrual as of 9/13/04 and Phase II, group 1 closed to accrual as of 5/10/06)

- Determine the toxicity of this regimen in these patients.

- Determine the clinical and pathological response rate and duration of response in

patients treated with this regimen.

- Determine drug sensitivity and resistance in patients treated with this regimen.

- Determine prognostic and predictive markers in patients treated with this regimen.

OUTLINE: This is a nonrandomized, multicenter, dose-escalation study of docetaxel and epirubicin.

- Phase I:

Group 1 (21-day regimen) (closed to accrual as of 09/13/04): Patients receive epirubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with objective response after 6 courses may receive additional therapy at the discretion of the physician. Group 2 (14-day regimen): Patients receive epirubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with objective response after 8 courses may receive additional therapy at the discretion of the physician. Cohorts of 3-6 patients receive escalating doses of epirubicin and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

- Phase II:

Group 1 (21-day regimen) (closed to accrual as of 5/10/06): Patients receive treatment as in phase I with epirubicin and docetaxel at the recommended Phase II dose. Group 2 (14-day regimen): Patients receive treatment as in phase I with epirubicin and docetaxel at the recommended Phase II dose. Patients are followed at 1 month, every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter. PROJECTED ACCRUAL: Approximately 90 patients will be accrued for this study.

Eligibility

Minimum age: 16 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

DISEASE CHARACTERISTICS:

- Histologically confirmed invasive adenocarcinoma of the breast, meeting any of the

following criteria:

- T4, NX, M0

- Any T, N2-N3, M0

- Inflammatory breast cancer (redness over at least one-third of the breast), M0

- No evidence of metastatic disease by chest x-ray, abdominal ultrasound or CT scan and

bone scan

- Diagnosed within the past 8 weeks

- Hormone receptor status:

- Not specified

PATIENT CHARACTERISTICS: Age

- 16 and over

Sex

- Female

Menopausal status

- Not specified

Performance status

- ECOG 0-2

Life expectancy

- Not specified

Hematopoietic

- Absolute granulocyte count at least 2,000/mm^3

- Platelet count at least 100,000/mm^3

- Hemoglobin at least 10 g/dL

Hepatic

- Bilirubin less than upper limit of normal (ULN)

- Must meet criteria for 1 of the following:

- ALT and AST no greater than 1. 5 times ULN AND alkaline phosphatase no greater

than 2. 5 times ULN

- ALT and AST normal AND alkaline phosphatase no greater than 5 times ULN

Renal

- Creatinine no greater than 1. 5 times ULN

Cardiovascular

- Resting LVEF normal by MUGA or echocardiogram

- No congestive heart failure

- No angina pectoris

- No myocardial infarction within the past year

- No uncontrolled hypertension

- No uncontrolled arrhythmias

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective non-hormonal contraception

- No other malignancy within the past 5 years except adequately treated nonmelanoma

skin cancer or curatively treated carcinoma in situ of the cervix

- No symptomatic peripheral neuropathy grade 2 or greater

- No active infection

- No history of significant neurological or psychiatric disorders, including dementia

or seizures

- No peptic ulcer

- No unstable diabetes mellitus

- No contraindication to dexamethasone

- No known sensitivity to E. coli-derived or polyethylene glycol products

- Willing to undergo core biopsies once prior to registration and core biopsies at 2

other timepoints while on study

- Geographically accessible for treatment and follow-up

PRIOR CONCURRENT THERAPY: Biologic therapy

- No prior immunotherapy for breast cancer

Chemotherapy

- No prior chemotherapy for breast cancer

Endocrine therapy

- No prior hormonal therapy for breast cancer

- No concurrent corticosteroids except for premedication or hypersensitivity reaction

- No concurrent oral contraception

Radiotherapy

- No prior radiotherapy for breast cancer

Surgery

- No prior surgery for breast cancer other than biopsy

Other

- No prior systemic therapy for breast cancer

- No other concurrent investigational drugs or anticancer treatment

- No concurrent preventative IV antibiotics

Locations and Contacts

CancerCare Manitoba, Winnipeg, Manitoba R3E 0V9, Canada

Atlantic Health Sciences Corporation, Saint John, New Brunswick E2L 4L2, Canada

Odette Cancer Centre, Toronto, Ontario M4N 3M5, Canada

Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario M5G 2M9, Canada

CHA-Hopital Du St-Sacrement, Quebec City, Quebec G1S 4L8, Canada

Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: February 2003
Last updated: January 16, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017